Key points are not available for this paper at this time.
ABSTRACT Objective This paper describes the implementation of preemptive clinical pharmacogenomics (PGx) testing linked to an automated electronic clinical decision support (CDS) system delivering clinically actionable PGx information to clinicians at the point of care at UCSF Health, a large Academic Medical Center. Methods A multidisciplinary team developed the strategic vision for the PGx program. The drug-gene interactions of interest were compiled, and actionable alleles were identified. A genotyping platform was selected and validated at the in-house laboratory. Following HIPAA protocols, genotype results were electronically transferred and stored in EPIC. CDS was developed and integrated with electronic prescribing. Results We developed a customized clinical PGx program for 56 medications and 15 genes. 233 MWs and 15 BPAs, approved by clinicians, were built into EPIC to deliver actionable clinical PGx information to clinicians. Conclusions Our multidisciplinary team successfully implemented preemptive PGx testing linked to point-of-care electronic CDS to guide clinicians with precise medication decision-making.
Tamraz et al. (Tue,) studied this question.